Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (34)

I-06Amelia Deitchman

Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models

Wednesday 10:30-12:00

I-13Vincent Madelain

Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study)

Wednesday 10:30-12:00

I-17Ben Margetts

Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children

Wednesday 10:30-12:00

I-63Leire Ruiz Cerdá

Modeling of Interferon effector pathway after viral infection

Wednesday 10:30-12:00

II-22Elin Svensson

Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis

Wednesday 15:10-16:30

II-23Lénaïg Tanneau

Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209

Wednesday 15:10-16:30

II-24Joel Tarning

Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis

Wednesday 15:10-16:30

II-33Eirini Tsotsou

Population pharmacokinetics of gentamycin in hospitalized ICU patients

Wednesday 15:10-16:30

II-37Sami Ullah

Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis

Wednesday 15:10-16:30

II-40Elodie Valade

Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers

Wednesday 15:10-16:30

II-50Thanaporn Wattanakul

Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria

Wednesday 15:10-16:30

III-07Jose Francis

Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients.

Thursday 09:50-11:20

III-13Silke Gastine

Population Pharmacokinetics of Micafungin in critically ill patients – evaluation of a fixed dose regimen

Thursday 09:50-11:20

III-15Parviz Ghahramani

Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions

Thursday 09:50-11:20

III-29Niklas Hartung

Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments

Thursday 09:50-11:20

III-33Gailing Li

Mechanism-Based Modeling In Chronic Heptatis B

Thursday 09:50-11:20

III-47Johannes Kast

Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin

Thursday 09:50-11:20

III-48Tatiana Khariton

Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 – a Novel Antibacterial Lysin

Thursday 09:50-11:20

III-50Yun Kim

A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects

Thursday 09:50-11:20

III-54Franziska Isabelle Kluwe

Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy

Thursday 09:50-11:20

III-60Anders Kristoffersson

A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates

Thursday 09:50-11:20

III-66Donghwan Lee

Population pharmacokinetic analysis of meropenem in Korean patients with acute infections

Thursday 09:50-11:20

IV-04Pascal André

Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute.

Thursday 14:45-16:15

IV-08Eduardo Asín-Prieto

An Immune quantitative network aimed for viral hepatitis B

Thursday 14:45-16:15

IV-15

Modelling body mass index trajectory in HIV-infected individuals

Thursday 14:45-16:15

IV-20Julie Bertrand

Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients

Thursday 14:45-16:15

IV-24Agnieszka Borsuk-De Moor

Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery

Thursday 14:45-16:15

IV-29Charles Burdet

Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers

Thursday 14:45-16:15

IV-30Unai Caballero

Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance

Thursday 14:45-16:15

IV-44Joannellyn Chiu

Pre-clinical Population PK Model of CF-301 – a Novel Antibacterial Lysin

Thursday 14:45-16:15

IV-53Miné De Kock

Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria.

Thursday 14:45-16:15

IV-60Paolo Denti

Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials

Thursday 14:45-16:15

IV-67Sulav Duwal

Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds

Thursday 14:45-16:15

IV-68Lisa Ehmann

Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients?

Thursday 14:45-16:15